First in the Series: Upcoming Webinar on Pharmaceutical IP Issues in China

On May 27, 2020, Berkeley Law will be hosting the first in a seven-part series on Chinese IP.  The series will provide CLE credit.  Attendees are also eligible for a certificate upon completion of the series.  You can choose to attend individual classes without the certificate, or the series ($50.00/$299.00).  Here is the information on the pharma program:

Session 1: May 27, 2020 – Pharmaceutical IP Issues / 4:30 P.M. (PT) – 90 min.

Pharmaceutical IP protection was a big “winner” in the Phase 1 Trade Agreement. How is China planning on implementing its commitments to improve protection for innovative chemical compounds and biologics? 

Speakers:

  • Chief Judge Randall Rader (ret.)
  • He Jing, Anjie Law Firm
  • Zhao Xu, East China University of Politics and Law
  • Tony Chen, Jones Day
  • Karen Guo, Novo Nordisk
  • Moderator: Mark Cohen, Berkeley Law

$50 single session registration fee
Register here

There will also be a separate round-table scheduled for June 8 on patent linkage in conjunction with this event (no additional fee).  Details to be announced on Wednesday.

The Webinar series will cover some of the “hottest” topics in China IP issues including trade secret protection, abusive trademark registrations, developments in copyright law, pharmaceutical IP developments, enforcement issues, licensing and antitrust, trade secrets, and the emerging different in patent prosecution practices in AI, software-enabled inventions and diagnostics.  Speakers include faculty from Berkeley Law and other institutions, former Chief Judges Rader and Michel, former USPTO Director Kappos, along with many other experts.    

Challenges for IP Protection in the Innovative Economy: The Case of Pharma in China

Attached are English and Chinese versions of a speech by USPTO Acting Director Teresa Rea that was first delivered at China Pharmaceutical University earlier this month.  The speech underscores the challenges for innovative pharmaceutical companies in China’s current IP environment.